G

ood morning, everyone, and how are you today? We are just fine, thank you, since a shiny sun and delicious breeze are enveloping the Pharmalot campus. We hope things are just as delightful wherever you may be. Now, though, the time has come to get cracking. Before we continue, however, we would like to note that we will break for a couple of days in observance of ancient traditions. But we will be back before you can say Jack Robinson, or Donald Trump, or how about Bernie Sanders? Well, whatever. Best of luck during the rest of the week and see you soon …

The U.K.’s National Institute for Health and Care Excellence recommended the Opdivo immunotherapy as a second-line treatment for some forms of lung cancer after Bristol-Myers Squibb (BMY) agreed to discount the price, Pharmaphorum explains. The arrangement comes a year after the cost-effectiveness watchdog initially offered to recommend coverage only for about one-third of the 1,300 eligible patients.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy